--- title: "Pluri (PLUR) news: delisting and Nasdaq notice" url: "https://aibio.space/companies/pluri/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PLUR delisting and Nasdaq notice news: Pluri gets Nasdaq extension to May 24, 2025 to regain stockholders' equity compliance. Pluri Inc." --- PLUR Pluri Inc. NASDAQ · Israel # Pluri (PLUR) news PLUR delisting and Nasdaq notice news Listings · 2025-09-12 ## [Pluri regains Nasdaq audit committee compliance after naming independent director](https://aibio.space/news/pluri-regains-nasdaq-audit-committee-compliance-after-naming/) Nasdaq confirmed the matter is closed after Pluri elected Eitan Ajchenbaum as an independent director and Audit Committee chair. The gap began after the June 30, 2025 annual meeting. ## Latest Pluri news 1. 2025-07-03 Listings [Pluri gets Nasdaq audit committee notice after director Doron Birger is not re-elected](https://aibio.space/news/pluri-gets-nasdaq-audit-committee-notice-after-director-doron-birger/) Pluri told Nasdaq it fell below the three-independent-director minimum for its audit committee after shareholders voted against director Doron Birger, who chaired it. The cure period ends no later than June 30, 2026, and the company says it will add an independent director. 2. 2025-04-25 Financings [Pluri swaps 976,139 shares held by director's company for pre-funded warrants](https://aibio.space/news/pluri-swaps-976-139-shares-held-directors-company-pre-funded-warrants/) The investor is a company wholly beneficially owned by director Alejandro Weinstein. The new warrants can be exercised only after shareholder approvals required by Nasdaq rules. 3. 2025-01-21 Listings [Pluri gets Nasdaq extension to May 24, 2025 to regain stockholders' equity compliance](https://aibio.space/news/pluri-gets-nasdaq-extension-may-24-2025-regain-stockholders-equity/) Nasdaq accepted Pluri's compliance plan after a November 25, 2024 deficiency letter. The company must show $2,500,000 in stockholders' equity by the deadline or may face delisting, and its shares keep trading as PLUR. ## Pluri at a glance - **Ticker**: PLUR - **Listing**: NASDAQ - **Country**: Israel - **Cash, Jun 30, 2026**: $3.5 million ### Related companies - [Evogene](https://aibio.space/companies/evogene/) NASDAQ: EVGN - [NRGENE TECHNOLOGIES LTD](https://aibio.space/companies/nrgene-technologies/) TASE: NRGN - [Compugen](https://aibio.space/companies/compugen/) NASDAQ: CGEN - [Matricelf](https://aibio.space/companies/matricelf/) TASE: MTLF - [Enlivex](https://aibio.space/companies/enlivex/) NASDAQ: ENLV - [Regentis Biomaterials](https://aibio.space/companies/regentis-biomaterials/) AMEX: RGNT - [Kamada](https://aibio.space/companies/kamada/) NASDAQ: KMDA - [Polyrizon](https://aibio.space/companies/polyrizon/) NASDAQ: PLRZ ### Also on NASDAQ - [Incannex Healthcare](https://aibio.space/companies/incannex-healthcare/) IXHL - [Sight Sciences](https://aibio.space/companies/sight-sciences/) SGHT - [NervGen Pharma](https://aibio.space/companies/nervgen-pharma/) NGEN - [LEMAITRE VASCULAR INC](https://aibio.space/companies/lemaitre-vascular/) LMAT - [Eocene](https://aibio.space/companies/eocene/) EOCN - [Lakewood-Amedex Biotherapeutics](https://aibio.space/companies/lakewood-amedex-biotherapeutics/) LABT ## What Pluri does Pluri Inc. is a biotechnology company built on a proprietary 3D cell expansion platform and an in-house, industrial-scale cell manufacturing facility. The platform supports two application areas: Human Health and Longevity, and Foodtech and Bio-Farming. In human health, the company develops placenta-derived cell therapy candidates. PLX-PAD is composed of maternal mesenchymal stromal cell-like cells and has been tested for acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, graft versus host disease and peripheral artery disease. It is also being developed for mild to moderate knee osteoarthritis as part of the PROTO program led by Charité Berlin Institute of Health Center for Regenerative Therapies. PLX-R18 was tested in a Phase I trial for incomplete recovery following hematopoietic cell transplantation. The company's allogeneic placental MAIT cell platform targets solid tumors. Partners named in the text include Bar-Ilan University's commercial arm BIRAD, which holds rights to develop PLX cells as a cocaine anti-addiction product, and Hemafund, a Ukrainian umbilical cord blood bank, whose collaboration on PLX-R18 is not currently active. | Product or program | What it is | Stage | |---|---|---| | PLX-PAD | Placenta-derived adherent stromal cells for several indications, including knee osteoarthritis | Clinical study approved by Germany's PEI in June 2025 | | PLX-R18 | Fetal MSC-like placenta-derived cells for incomplete recovery after transplantation and acute radiation syndrome | Tested in a Phase I trial | | Placental MAIT cell immunotherapy | Allogeneic immunotherapy platform for solid tumors | Platform launched in May 2024 | | PluriCDMO | Development and manufacturing services for cell-based products | Offered | Summarised from the company's [10-K filed Sep 10, 2026](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/ea0304639-10k_pluri.htm). ## Pluri annual financials | Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 | |---|---|---| | Revenue | [$1.0 million](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/) | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/) | | Research and development | [$15.1 million](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/) | [$12.9 million](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/) | | Net income (loss) | [-$23.8 million](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/) | [-$22.6 million](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/) | | Cash from operations | [-$19.6 million](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/) | [-$18.2 million](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/) | | Cash and equivalents | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/) | [$5.9 million](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/) | Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $3.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Pluri Was Pluri delisted? Our latest story on this, dated Jan 21, 2025: "Pluri gets Nasdaq extension to May 24, 2025 to regain stockholders' equity compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pluri-gets-nasdaq-extension-may-24-2025-regain-stockholders-equity/). Has Pluri received a Nasdaq deficiency notice? Our latest story on this, dated Jan 21, 2025: "Pluri gets Nasdaq extension to May 24, 2025 to regain stockholders' equity compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pluri-gets-nasdaq-extension-may-24-2025-regain-stockholders-equity/). What is the ticker symbol of Pluri? Pluri Inc. trades under the ticker PLUR on NASDAQ. Where is Pluri listed? Pluri Inc. is listed on NASDAQ. Our directory also records these other listings: TASE:PLUR. What is the SEC CIK of Pluri? The SEC Central Index Key (CIK) for Pluri Inc. is 1158780. Its filings are on SEC EDGAR. How many shares does Pluri have outstanding? 12,344,736 shares as of 2026-09-09, per the cover page of its 10-K filed 2026-09-10. Which country or territory is Pluri listed under? Our directory records Pluri Inc. under Israel. What does Pluri do? Our directory classifies Pluri Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Pluri? The ISIN recorded for Pluri Inc. is US72942G2030. Does aibio.space cover Pluri? aibio.space lists Pluri Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Pluri incorporated? SEC records list its state or country of incorporation as NV. What does Pluri develop? Pluri Inc. is a biotechnology company built on a proprietary 3D cell expansion platform and an in-house, industrial-scale cell manufacturing facility. The platform supports two application areas: Human Health and Longevity, and Foodtech and Bio-Farming. What is PLX-PAD from Pluri? PLX-PAD: Placenta-derived adherent stromal cells for several indications, including knee osteoarthritis Stage: Clinical study approved by Germany's PEI in June 2025. What is PLX-R18 from Pluri? PLX-R18: Fetal MSC-like placenta-derived cells for incomplete recovery after transplantation and acute radiation syndrome Stage: Tested in a Phase I trial. What was Pluri's revenue last year? $1.0 million for the fiscal year ended Jun 30, 2026, as reported to the SEC. ## Investor discussion: Pluri Members talk about Pluri (PLUR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Pluri, newest first. Each line links the filing it comes from. 1. 2026-09-11 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098906/ea0304787-s3_pluri.htm) 2. 2026-07-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390026077548/ea0297769-8k_pluri.htm) 3. 2026-03-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390026022025/ea0279347-8k_pluri.htm) 4. 2026-01-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390026006685/ea0273651-8k_pluri.htm) 5. 2025-09-17 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390025088578/ea0256130-10k_pluriinc.htm) 6. 2025-09-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390025087052/ea0257121-8k_pluri.htm) 7. 2025-07-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,5.07). [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390025061364/ea0248143-8k_pluri.htm) 8. 2025-05-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390025040816/ea0241352-8k_pluri.htm) 9. 2025-04-25 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390025035668/ea0239604-8k_pluri.htm) 10. 2025-01-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390025007698/ea0228987-8k_pluri.htm) 11. 2025-01-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390025004755/ea0227893-8k_pluri.htm) 12. 2024-11-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1158780/000121390024103469/ea0222850-8k_pluri.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PLUR on TradingView](https://www.tradingview.com/symbols/NASDAQ-PLUR/). ## SEC filings and registration - **SEC name**: Pluri Inc. - **CIK**: 1158780 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: PLUR (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: MATAM ADVANCED TECHNOLOGY PARK, HAIFA - **Phone**: 972-74-710-7171 - **Shares outstanding**: 12,344,736 as of 2026-09-09 (10-K filed 2026-09-10) - **Former names**: PLURISTEM THERAPEUTICS INC; PLURISTEM LIFE SYSTEMS INC; AI SOFTWARE INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1158780/000121390026111015/ea0309096-8k_pluri.htm) filed 2026-10-20 - [S-1](https://www.sec.gov/Archives/edgar/data/1158780/000121390026107182/ea0307692-s1_pluri.htm) filed 2026-10-06 - [S-3](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098906/ea0304787-s3_pluri.htm) filed 2026-09-11 - [10-K](https://www.sec.gov/Archives/edgar/data/1158780/000121390026098862/ea0304639-10k_pluri.htm) filed 2026-09-10 - [424B5](https://www.sec.gov/Archives/edgar/data/1158780/000121390026094704/ea0303747-424b5_pluri.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1158780/000121390026094638/ea0303582-8k_pluri.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1158780/000121390026090738/ea0302362-8k_pluri.htm) filed 2026-08-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1158780/000121390026077960/ea0297856-8k_pluri.htm) filed 2026-07-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001158780), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Pluri Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PLUR, recorded under Israel. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Pluri Inc. - **Ticker**: PLUR - **Listing**: NASDAQ - **Country or territory**: Israel - **Business scope**: Biotechnology - **ISIN**: US72942G2030 - **Other listed symbols**: TASE:PLUR - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PLUR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/pluri/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Pluri (PLUR) news: delisting and Nasdaq notice", 2026-10-31, https://aibio.space/companies/pluri/